PIV-3 vaccine National Institutes of Health/Aviron.
Wyeth-Lederle, Aviron and NIH are developing a live intranasal parainfluenza virus (PIV) type 3 vaccine (cp45 vaccine). The vaccine is in phase II/III trials with Aviron [411386], and phase I trials with Wyeth-Lederle [408940]. It consists of a temperature-sensitive PIV-3 virus attenuated with an imported L gene mutation. This addition renders the virus 5-fold more restricted for replication in the respiratory tract of chimpanzees and also more temperature-sensitive [336999].